Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study
Giannini et al.
, Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A..
, Nutrients, doi:10.3390/nu13010219
Retrospective 91 hospitalized patients, 36 treated with high-dose cholecalciferol, showing lower combined death/ICU admission with treatment.
Authors also analyze the relationship with comorbidity burden, finding that the positive effect of high-dose cholecalciferol on the combined endpoint was significantly amplified with increasing comorbidity burden.
risk of death/ICU, 36.6% lower, RR 0.63, p = 0.13, treatment 14 of 36 (38.9%), control 29 of 55 (52.7%), NNT 7.2, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Giannini et al., 14 Jan 2021, retrospective, Italy, peer-reviewed, 21 authors, dosage 200,000IU days 1-2.
Effectiveness of In-Hospital Cholecalciferol Use on Clinical
Outcomes in Comorbid COVID-19 Patients:
A Hypothesis-Generating Study
Sandro Giannini 1, * , Giovanni Passeri 2 , Giovanni Tripepi 3 , Stefania Sella 1 , Maria Fusaro 1,4 ,
Gaetano Arcidiacono 1 , Marco Onofrio Torres 1 , Alberto Michielin 1 , Tancredi Prandini 1 , Valeria Baffa 1 ,
Andrea Aghi 1 , Colin Gerard Egan 5 , Martina Brigo 6 , Martina Zaninotto 7 , Mario Plebani 7 , Roberto Vettor 8 ,
Paola Fioretto 8 , Maurizio Rossini 9 , Alessandro Vignali 2 , Fabrizio Fabris 1 and Francesco Bertoldo 6
Citation: Giannini, S.; Passeri, G.;
Tripepi, G.; Sella, S.; Fusaro, M.;
Arcidiacono, G.; Torres, M.O.;
Michielin, A.; Prandini, T.; Baffa, V.;
et al. Effectiveness of In-Hospital
Clinica Medica 1, Department of Medicine, University of Padova, 35128 Padova, Italy;
firstname.lastname@example.org (S.S.); email@example.com (M.F.); firstname.lastname@example.org (G.A.);
email@example.com (M.O.T.); firstname.lastname@example.org (A.M.);
email@example.com (T.P.); firstname.lastname@example.org (V.B.); email@example.com (A.A.);
Unit of Clinica e Terapia Medica, Department of Medicine and Surgery, University of Parma,
43126 Parma, Italy; firstname.lastname@example.org (G.P.); email@example.com (A.V.)
National Research Council (CNR), Institute of Clinical Physiology (IFC),
Clinical Epidemiology of Renal Diseases and Hypertension, Ospedali Riuniti,
89124 Reggio Calabria, Italy; firstname.lastname@example.org
National Research Council (CNR), Institute of Clinical Physiology (IFC), 56124 Pisa, Italy
CE Medical Writing, 56021 Pisa, Italy; email@example.com
Internal Medicine, Department of Medicine, University Hospital AOUI, 37134 Verona, Italy;
firstname.lastname@example.org (M.B.); email@example.com (F.B.)
Laboratory Medicine Unit, Department of Medicine, University of Padova, 35128 Padova, Italy;
firstname.lastname@example.org (M.Z.); email@example.com (M.P.)
Clinica Medica 3, Department of Medicine, University of Padova, 35128 Padova, Italy;
firstname.lastname@example.org (R.V.); email@example.com (P.F.)
Rheumatology Unit, Department of Medicine, University of Verona, 37134 Verona, Italy;
Correspondence: firstname.lastname@example.org; Tel.: +39-049-8212169
Cholecalciferol Use on Clinical
Outcomes in Comorbid COVID-19
Patients: A Hypothesis-Generating
Study. Nutrients 2021, 13, 219.
Received: 16 December 2020
Accepted: 11 January 2021
Published: 14 January 2021
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://
Abstract: Little information is available on the beneficial effects of cholecalciferol treatment in comorbid patients hospitalized for COVID-19. The aim of this study was to retrospectively examine
the clinical outcome of patients receiving in-hospital high-dose bolus cholecalciferol. Patients with a
positive diagnosis of SARS-CoV-2 and overt COVID-19, hospitalized from 15 March to 20 April 2020,
were considered. Based on clinical characteristics, they were supplemented (or not) with 400,000..
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.